期刊文献+

免疫调节因子在膀胱癌患者血清和血浆中的表达差异及其临床意义

The clinical significance of immune regulatory factors in serum and plasma of urothelial cell carcinoma of the bladder
下载PDF
导出
摘要 目的研究分析膀胱癌和泌尿系结石患者血清和血浆中TGF-β1、IL-6和IL-10等炎症因子的表达差异及其临床意义。方法应用酶联免疫吸附测定方法(ELISA)检测2015年7月至2016年2月我院42例确诊膀胱癌患者(肿瘤组)及30例泌尿系结石患者(对照组)血清和血浆中TGF-β1、IL-6和IL-10的表达水平。42例患者中,肿瘤最大径≤3cm 26例,>3cm 16例。肿瘤单发35例,多发7例。肿瘤分期Ta~T1期29例,T2~T4期13例。淋巴结无转移40例,有转移2例。非肌层浸润性膀胱癌24例,肌层浸润性膀胱癌18例。病理分级低分级20例,高分级22例。应用Wilcoxon非参数检验法分析炎症因子在血清和血浆中的表达差异,利用Kruskal-Wallis法进一步评价膀胱癌患者血清和血浆中TGF-β1的表达差异和其临床意义。结果对照组和肿瘤组血清中TGF-β1的表达均高于血浆中的表达量(P<0.0001);而IL-6和IL-10匹配血清和血浆中的表达差异无统计学意义(P>0.05)。血清中TGF-β1的表达在肿瘤组高于对照组(P<0.01)。膀胱癌患者血清中TGF-β1表达与肿瘤分期和病理分级成正相关(P<0.05);患者血浆中TGF-β1表达与临床参数不相关(P>0.05)。结论 TGF-β1在膀胱癌和泌尿系结石患者血清中的表达量明显高于其在血浆中的表达;膀胱癌患者血清而非血浆中TGF-β1的表达与肿瘤分期和病理分级呈正相关,提示血清中TGF-β1表达具有成为监测膀胱癌进展指标的潜能。 Objective The purpose of this study was to analyze the expression of TGF-β1,IL-6 and IL -10 in the matched serum and plasma of patients with urologic diseases,and to investigate their clinical significance. Methods The serum and plasma samples were obtained from 42 patients diagnosed bladder cancer and 30 patients diagnosed urolithiasis from July 2015 to February 2016. The expression of TGF -β1,IL-6 and IL-10 in the serum and plasma were assessed by enzyme-linked immunosorbent assay (ELISA). Nonparametric Wilcoxon analysis was used to evaluate the differences of cytokine expression in matched serum and plasma. Kruskal-Wallis analysis was applied to evaluate the clinical significance of TGF-β1 expression in matched serum and plasma collected from patients with bladder cancer. Result The concentration of TGF-β1 in serum is higher than it in the matched plasma(P<0.0001). However, the concentrations of IL-6 and IL-10 had no statistical significance in the matched serum group and plasma group(P>0.05). Compared to the Urolithiasis group,the level of TGF-β1 in tumor group was significantly elevated(P<0.01). Moreover,the level of TGF-β1 in serum was positively associated with tumor stage and grade(P<0.05). In contrast,the level of TGF-β1 in plasma group had no statistically significance(P>0.05). Conclusion The expression of TGF-β1 in serum,but not plasma,was positively.
作者 杨美华 毕峻铭 王博 黄健 YANG Meihua;BI Junming;WANG Bo;HUANG Jian(Department of Urology,Sun Yat-sen Memorial Hospital,Sun Yat-sen University,Guangzhou 510120,China)
出处 《岭南现代临床外科》 2019年第1期48-51,56,共5页 Lingnan Modern Clinics in Surgery
基金 国家自然科学基金(81372729 81402106)
关键词 膀胱癌 血清 血浆 TGF-Β1 urothelial cell carcinoma of the bladder serum plasma TGF-β1
  • 相关文献

参考文献3

二级参考文献22

  • 1Kanayama H O,Cancer,1998年,82卷,1359页
  • 2Farina A R,Int J Cancer,1998年,75卷,721页
  • 3Kim I Y,Cancer Res,1996年,56卷,44页
  • 4Kim JH,Shariat SF, Kim IY, et al. Predictive value of expression of transforming growth factor-beta( 1 ) and its receptors in transitional cell carcinoma of the urinary bladder.Cancer,2001,92:1475-1483.
  • 5Eder IE, Stenzl A, Hobisch A, et al. Transforming growth factors-beta1 and beta2 in serum and urine from patients with bladder carcinoma. J Urol, 1996,156:953-957.
  • 6Shariat SF, Kim JH, Andrews B, et al. Preoperative plasma levels of transforming growth factor beta ( 1 ) strongly predict clinical out come in patients with bladder carcinoma. Cancer, 2001,92: 2985 -2992.
  • 7Cherifa A,Alain B,LaRue H,et al.Toll-like receptors in normal and malignant human bladders[J].J Urol,2011,185(5):1915-1921.
  • 8Hu F,a Dzaye OD,Hahn A,et al.Glioma-derived versican promotes tumor expansion via glioma-associated microglial/ macrophages Toll-like receptor 2 signaling[J].Neuro Oncol,2015,17(2):200-210.
  • 9Shi W,Su L,Li Q,et al.Suppression of toll-like receptor 2 expression inhibits the bioactivity of human hepatocellular carcinoma[J].Tumour Biol,2014,35(10):9627-9637.
  • 10Maruyama A,Shime H,Takeda Y,et al.Pam2 lipopeptides systemically increase myeloid-derived suppressor cells through TLR2 signaling[J].Biochem Biophys Res Commun,2015,457(3):445-450.

共引文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部